We're bringing you highlights from the 67th ASH Annual Meeting with a summary of selected scientific sessions on CML

🌟 Education Spotlight Session: The changing face of CML

Chairs: Gabriela Soriano Hobbs (USA)
This Education Spotlight Session provided a comprehensive, practice-oriented update on two central pillars of modern CML management:
(1) selecting optimal frontline therapy, and
(2) safely implementing treatment-free remission (TFR). 

Professor Jorge Cortes explored how evolving tyrosine kinase inhibitor (TKI) options, safety considerations, comorbidities, additional mutations (ASXL1), and patient goals shape first-line decision-making in 2025. 
Professor François-Xavier Mahon, a pioneer of TFR, presented the foundations, predictive factors, and long-term outcomes that guide treatment discontinuation today.

Together, the talks emphasised patient-centred care, biological heterogeneity, and the need for individualised strategies that optimise both survival and quality of life of patients with CML.

Our key takeaways from the presentations:

Read more